Compare MAIR & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAIR | HALO |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.0B |
| IPO Year | 2026 | 2001 |
| Metric | MAIR | HALO |
|---|---|---|
| Price | $22.67 | $126.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $38.67 | ★ $108.78 |
| AVG Volume (30 Days) | ★ 2.2M | 2.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.26 | ★ 3.11 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $18.72 | $34.69 |
| Revenue Next Year | $14.03 | $11.65 |
| P/E Ratio | $88.81 | ★ $39.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.96 | $61.23 |
| 52 Week High | $41.89 | $125.43 |
| Indicator | MAIR | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 74.21 |
| Support Level | N/A | $105.27 |
| Resistance Level | $25.55 | N/A |
| Average True Range (ATR) | 0.91 | 3.51 |
| MACD | 0.01 | 1.11 |
| Stochastic Oscillator | 24.39 | 99.04 |
Madison Air Solutions Corp is an HVAC and indoor air-quality technology company. Its segments are Commercial and Residential. It generates the majority of its revenue from the Commercial segment, which includes Commercial businesses that deliver well-engineered, custom, and semi-custom air quality systems to support process control, regulatory compliance, energy efficiency, and productivity in mission-critical environments; and the Residential segment, anchored by trusted brands like AprilAire, Broan-NuTone, Zephyr, and Others. Its geographic areas are the U.S, the Americas, Europe, and Other. The group generates the majority of its revenue from the U.S market.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.